Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + mitomycin
- Development stage
- Unknown
- Lead developer
- Jordan Kharofa
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
5-fluorouracil + mitomycin is a combination chemotherapy regimen primarily used as a radiosensitizer in the definitive treatment of squamous cell carcinoma of the anal canal. 5-fluorouracil (5-FU) is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, thereby disrupting DNA synthesis. Mitomycin (also known as mitomycin C) is an antitumor antibiotic that acts as a potent DNA cross-linking agent, inducing DNA damage and inhibiting replication. In the clinical trial led by Jordan Kharofa at the University of Cincinnati (NCT03397459), this regimen is administered concurrently with Intensity Modulated Proton Therapy (IMPT) to evaluate the feasibility of reducing treatment-related toxicities in patients with stage T2-4 anal cancer compared to traditional photon-based radiation therapy.
- Brand names
- AdrucilMutamycin
- Other names
- 5-FU + Mitomycin5-FU + Mitomycin CMitomycin + 5-FluorouracilNigro protocol
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + mitomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + mitomycin.